vs
Ginkgo Bioworks Holdings, Inc.（DNA）与RxSight, Inc.（RXST）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是RxSight, Inc.的1.0倍（$33.4M vs $32.6M），RxSight, Inc.同比增速更快（-18.9% vs -23.8%），RxSight, Inc.自由现金流更多（$-2.3M vs $-47.7M），过去两年RxSight, Inc.的营收复合增速更高（5.1% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
RxSight是一家医疗科技企业，专注于研发和商业化适用于白内障及屈光晶状体置换手术的可调光人工晶状体产品，其核心产品支持术后通过专用照光设备调整晶状体度数，为全球眼科诊疗市场提供优化的术后视力解决方案。
DNA vs RXST — 直观对比
营收规模更大
DNA
是对方的1.0倍
$32.6M
营收增速更快
RXST
高出4.9%
-23.8%
自由现金流更多
RXST
多$45.4M
$-47.7M
两年增速更快
RXST
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $32.6M |
| 净利润 | — | $-9.2M |
| 毛利率 | — | 77.5% |
| 营业利润率 | -211.9% | -34.8% |
| 净利率 | — | -28.1% |
| 营收同比 | -23.8% | -18.9% |
| 净利润同比 | — | -54.1% |
| 每股收益（稀释后） | $-1.41 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARXST
| Q4 25 | $33.4M | $32.6M | ||
| Q3 25 | $38.8M | $30.3M | ||
| Q2 25 | $49.6M | $33.6M | ||
| Q1 25 | $48.3M | $37.9M | ||
| Q4 24 | $43.8M | $40.2M | ||
| Q3 24 | $89.0M | $35.3M | ||
| Q2 24 | $56.2M | $34.9M | ||
| Q1 24 | $37.9M | $29.5M |
净利润DNARXST
| Q4 25 | — | $-9.2M | ||
| Q3 25 | $-80.8M | $-9.8M | ||
| Q2 25 | $-60.3M | $-11.8M | ||
| Q1 25 | $-91.0M | $-8.2M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-56.4M | $-6.3M | ||
| Q2 24 | $-217.2M | $-6.1M | ||
| Q1 24 | $-165.9M | $-9.1M |
毛利率DNARXST
| Q4 25 | — | 77.5% | ||
| Q3 25 | — | 79.9% | ||
| Q2 25 | — | 74.9% | ||
| Q1 25 | — | 74.8% | ||
| Q4 24 | — | 71.6% | ||
| Q3 24 | — | 71.4% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 70.1% |
营业利润率DNARXST
| Q4 25 | -211.9% | -34.8% | ||
| Q3 25 | -231.8% | -40.1% | ||
| Q2 25 | -132.1% | -41.6% | ||
| Q1 25 | -184.1% | -28.2% | ||
| Q4 24 | -236.3% | -21.5% | ||
| Q3 24 | -62.0% | -26.1% | ||
| Q2 24 | -396.7% | -23.9% | ||
| Q1 24 | -469.1% | -36.2% |
净利率DNARXST
| Q4 25 | — | -28.1% | ||
| Q3 25 | -207.9% | -32.4% | ||
| Q2 25 | -121.6% | -35.0% | ||
| Q1 25 | -188.2% | -21.6% | ||
| Q4 24 | — | -14.8% | ||
| Q3 24 | -63.3% | -17.9% | ||
| Q2 24 | -386.4% | -17.4% | ||
| Q1 24 | -437.3% | -30.8% |
每股收益（稀释后）DNARXST
| Q4 25 | $-1.41 | $-0.22 | ||
| Q3 25 | $-1.45 | $-0.24 | ||
| Q2 25 | $-1.10 | $-0.29 | ||
| Q1 25 | $-1.68 | $-0.20 | ||
| Q4 24 | $-1.91 | $-0.14 | ||
| Q3 24 | $-1.08 | $-0.16 | ||
| Q2 24 | $-4.23 | $-0.16 | ||
| Q1 24 | $-3.32 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $228.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $275.7M |
| 总资产 | $1.1B | $311.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNARXST
| Q4 25 | $422.6M | $228.1M | ||
| Q3 25 | $495.5M | $227.5M | ||
| Q2 25 | $559.4M | $227.5M | ||
| Q1 25 | $325.3M | $229.3M | ||
| Q4 24 | $561.6M | $237.2M | ||
| Q3 24 | $616.2M | $237.1M | ||
| Q2 24 | $730.4M | $233.3M | ||
| Q1 24 | $840.4M | $125.4M |
股东权益DNARXST
| Q4 25 | $508.6M | $275.7M | ||
| Q3 25 | $559.8M | $276.0M | ||
| Q2 25 | $613.0M | $278.0M | ||
| Q1 25 | $647.4M | $279.3M | ||
| Q4 24 | $716.1M | $281.2M | ||
| Q3 24 | $797.9M | $277.3M | ||
| Q2 24 | $833.1M | $275.2M | ||
| Q1 24 | $987.3M | $163.9M |
总资产DNARXST
| Q4 25 | $1.1B | $311.8M | ||
| Q3 25 | $1.2B | $308.5M | ||
| Q2 25 | $1.2B | $309.0M | ||
| Q1 25 | $1.3B | $313.0M | ||
| Q4 24 | $1.4B | $318.6M | ||
| Q3 24 | $1.5B | $310.5M | ||
| Q2 24 | $1.6B | $305.5M | ||
| Q1 24 | $1.6B | $183.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $-2.3M |
| 自由现金流率自由现金流/营收 | -142.8% | -6.9% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-19.3M |
8季度趋势，按日历期对齐
经营现金流DNARXST
| Q4 25 | $-47.7M | $-1.1M | ||
| Q3 25 | $-31.6M | $-1.2M | ||
| Q2 25 | $-40.3M | $-4.4M | ||
| Q1 25 | $-51.5M | $-8.8M | ||
| Q4 24 | $-42.4M | $-4.3M | ||
| Q3 24 | $-103.5M | $650.0K | ||
| Q2 24 | $-84.4M | $-4.0M | ||
| Q1 24 | $-89.3M | $-9.3M |
自由现金流DNARXST
| Q4 25 | $-47.7M | $-2.3M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | $-40.3M | $-5.9M | ||
| Q1 25 | $-59.1M | $-9.4M | ||
| Q4 24 | $-56.1M | $-5.1M | ||
| Q3 24 | $-118.6M | $-453.0K | ||
| Q2 24 | $-111.4M | $-5.5M | ||
| Q1 24 | $-96.0M | $-11.3M |
自由现金流率DNARXST
| Q4 25 | -142.8% | -6.9% | ||
| Q3 25 | — | -5.8% | ||
| Q2 25 | -81.2% | -17.6% | ||
| Q1 25 | -122.4% | -24.8% | ||
| Q4 24 | -128.0% | -12.7% | ||
| Q3 24 | -133.2% | -1.3% | ||
| Q2 24 | -198.2% | -15.9% | ||
| Q1 24 | -252.9% | -38.2% |
资本支出强度DNARXST
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.1% | 4.6% | ||
| Q1 25 | 15.8% | 1.5% | ||
| Q4 24 | 31.3% | 2.1% | ||
| Q3 24 | 16.9% | 3.1% | ||
| Q2 24 | 48.1% | 4.4% | ||
| Q1 24 | 17.7% | 6.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |
